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Abstract
The association between the disease-free interval (DFI) and survival after a locoregional re-
currence (LRR) or second primary (SP) breast cancer remains uncertain. The objective of
this study is to clarify this association to obtain more information on expected prognosis.
Women first diagnosed with early breast cancer between 2003–2006 were selected from
the Netherlands Cancer Registry. LRRs and SP tumours within five years of first diagnosis
were examined. The five-year period was subsequently divided into three equal intervals.
Prognostic significance of the DFI on survival after a LRR or SP tumour was determined
using Kaplan-Meier estimates and multivariable Cox regression analysis. Follow-up was
complete until January 1, 2014. A total of 37,278 women was included in the analysis. LRRs
or SP tumours were diagnosed in 890 (2,4%) and 897 (2,4%) respectively. Longer DFI was
strongly and independently related to an improved survival after a LRR (long versus short:
HR 0.65, 95% CI 0.48–0.88; medium versus short HR 0.81, 95% CI 0.65–1.01). Other fac-
tors related to improved survival after LRR were younger age (<70 years) and surgical re-
moval of the recurrence. No significant association was found between DFI and survival
after SP tumours. This is the first study to explore the association between the DFI and sur-
vival after recurrence in a nationwide population-based cancer registry. The DFI before a
LRR is an independent prognostic factor for survival, with a longer DFI predicting better
prognosis.
Introduction
Breast cancer-related mortality is decreasing in many countries because of earlier diagnosis
and improved treatment modalities [1,2]. After treatment patients receive follow-up care to
improve life expectancy by detecting recurrence of breast cancer in an asymptomatic stage.
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Recurrence of breast cancer can be a local recurrence (LR), regional recurrence (RR), second
primary (SP) tumour or distant metastasis (DM). Early detection and treatment of DM does
not lead to better outcomes and is therefore not an aim of follow-up care. Presence of a LR
and/or RR can be defined as locoregional recurrence (LRR). The majority of LRRs are diag-
nosed within five years of the primary tumour [3]. LRR rates vary between 3% for patients with
stage T1N0 who underwent mastectomy to 13% for patients with nodal involvement and
breast-conserving surgery [4–6]. SP breast cancer (diagnosed at least three months from the
primary tumour diagnosis [7] and with different primary location and morphology) occurs in
2–6% of the patients [8–12].
The time between treatment of the primary tumour and the detection of a recurrence is
known as the disease-free interval (DFI). The effect of the DFI on the prognosis after a LRR or
SP tumour is not well established. Previous reports defined short DFI as the first five years after
the primary tumour and long as the following years [13–16], or results were based on a single
institution or small patient series [17–20]. If the distinction is made of a short DFI being within
the first five years after diagnosis and a long DFI the following years, a long DFI is associated
with favourable outcomes [13–16]. In a study with 391 women treated with breast-conserving
surgery and radiotherapy Fredriksson et al. [21] also observed that a short DFI before a LR has
a negative impact on survival. Yet based on 133 patients from two randomised trials Van Tien-
hoven et al. [3] found the DFI to be prognostic only for the time to subsequent recurrence and
not an independent prognostic factor for survival. The aim of this study was to explore the rela-
tion between the DFI and survival after a LRR or SP tumour within five years of treatment of
the primary breast cancer, based on a nationwide population.
Patients and Methods
Study population
Patients were selected from the Netherlands Cancer Registry (NCR), a nationwide population-
based registry, which has recorded almost all newly diagnosed tumours since 1989. Notifica-
tions are obtained from the nationwide Pathology Automated Archives (PALGA). Specially
trained registration clerks record the information on patient, tumour and treatment character-
istics directly from the patient files, as well as data concerning recurrences within the first five
years following primary breast cancer. The information from the patient records was anon-
ymized and de-identified prior to analysis by the Comprehensive Cancer Centre the Nether-
lands (IKNL). The authors had consent from the Advisory Committee of the IKNL. The study
did not need approval of the Medical Ethical Committee (METc), while there was no direct pa-
tient contact and according to local regulations in the Netherlands (WMO) only studies with
high burden for patients have to be reviewed.
Women diagnosed with primary invasive breast cancer between 2003 and 2006 without
DM, previous, or synchronous tumours (diagnosed within three months after the first tumour
[7]), treated with curative intent and without neo-adjuvant systemic treatment were selected
from the registry (N = 37,278). Patients were treated with curative intent if the tumour was sur-
gically removed and no macroscopic residual disease was left. In case of microscopic residue,
the patient should have had adjuvant treatment. Of the selected patients, 1,787 (4.8%) devel-
oped a LRR or SP tumour within the first five years following primary breast cancer treatment.
Only first or synchronous LRRs or SP tumours were considered.
Statistical analyses
The DFI was measured from the date of final surgery of the primary tumour to the date of LRR
or SP tumour diagnosis. To analyse the effect of the DFI on survival after a LRR or SP tumour,
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the five year period after the primary breast cancer was divided into three equal intervals: (1)
patients with a LRR or SP tumour diagnosed within 608 days were considered to have a short
DFI; (2) between 609–1217 days a medium DFI; and (3) after 1217 days a long DFI. Overall
survival time was measured from the date of final surgery of the primary tumour to death or
the end of the study period (January 1, 2014) and was used for the comparison with women
without a recurrence. Survival after the LRR or SP tumour was used for the comparisons be-
tween the different DFI categories and determined from the date of diagnosis of the LRR or SP
tumour until death or the end of the study period. Follow-up was complete by linkage with the
Dutch municipal civil registry until January 1, 2014, after which surviving patients were
censored.
The patient, tumour, and treatment characteristics shown in Tables 1 and 2 were assessed
for their influence on survival after a LRR or SP tumour using Kaplan-Meier estimates and the
log-rank test for equality of survivor functions. To reveal differences in the characteristics be-
tween categorical variables, χ2 tests were used. Variables with probability values<0.1 on the
log-rank test were included in the multivariable analysis. In the Cox proportional hazards
model backward selection was used to find the variables with significant influence on survival
after the LRR or SP tumour; p-values of<0.05 were considered statistically significant. This led
to inclusion of the following variables: DFI category, type of recurrence, age, tumour grade ac-
cording to Bloom and Richardson [22], size, lymph node status and hormone receptor status
(ER and PR) of the primary tumour, and surgical removal of the recurrence. Interaction be-
tween the variables was tested by adding interaction terms into the model. The Cox propor-
tional hazards assumption was tested both numerically and graphically. Stratification into
short, medium and long DFIs and stratification for LRRs and SP tumours was performed to re-
veal possible differences in the influence of the covariates for the different categories.
Missing values from the variables included in the Cox proportional hazards model were
multiple imputed using chained equations [23, 24]. The HER2neu status had a relatively high
percentage of missing values (60%) while it has only been registered on a nation-wide basis
since 2004. Missing values were considered to occur randomly, which validates the use of im-
putation. All analyses were performed using STATA version 12 software.
Results
Characteristics
Of the 1,787 patients with a recurrence, 33% developed a LR, 13% a RR, 4% synchronous LRRs
and 50% SP breast cancer. Almost all of the SP tumours (95%) were contralateral. Median
length of the DFI after treatment of the primary tumour was 2.5 years. Compared to women
with LRRs, women with SP tumours had less often ductal primary tumours, had a smaller pri-
mary tumour with a lower grade, less nodal involvement and more often a positive hormone
status (both ER and PR).
Treatment
The treatment of the LRR appeared to diverge from the treatment of the primary tumour
(Table 3). Of the women with a LRR, 59% received surgery; 76% of the women with a LR and
15% with a RR. The patients without surgery for their LRR were treated with radiotherapy in
59% of the cases. In contrast, the treatment of SP tumours only diverged from the treatment of
the primary tumour with regard to the same type of therapy (Table 4). The SP tumours were
surgically removed in 96% of the cases. Differences in treatment of LRRs were also found when
comparing the DFI groups: women with a LRR and a short DFI received less surgery, more
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Table 1. Patient and primary tumour characteristics, for LRRs stratified by length of the DFI and tested for differences between the DFI groups.
Without LRR/SP SP LRR Length of DFI P
Short Medium Long
% N % N % N % N % N %
Total 35,491 897 890 299 348 243
Age category 0.034
<70 77.3 713 79.5 690 77.5 221 73.9 267 76.7 202 83.1
70 22.7 184 20.5 200 22.5 78 26.1 81 23.3 41 16.9
Histologic type 0.048
Ductal 79.4 672 74.9 740 83.1 263 88.0 288 82.8 189 77.8
Lobular 10.7 107 11.9 82 9.2 20 6.7 29 8.3 33 13.6
Mixed 4.2 54 6.0 27 3.0 5 1.7 13 3.7 9 3.7
Other 5.7 64 7.1 41 4.6 11 3.7 18 5.2 12 4.9
Grade <0.001
I,II 66.9 644 76.6 440 54.0 115 41.8 167 52.5 158 71.2
III 33.1 197 23.4 375 46.0 160 58.2 151 47.5 64 28.8
Unknown 56 75 24 30 21
Tumour size <0.001
2 cm 61.1 643 72.3 469 53.7 121 41.4 194 56.4 154 64.7
>2 cm 38.8 246 27.7 405 46.3 171 58.6 150 43.6 84 35.3
Unknown 8 16 7 4 5
Multifocal 0.238
No 84.8 558 81.8 507 79.1 184 80.7 187 75.7 136 81.9
Yes 15.2 124 18.2 134 20.9 44 19.3 60 24.3 30 18.1
Unknown 215 249 71 101 77
Lymph node status 0.025
Negative 61.3 660 74.7 503 58.1 155 53.1 189 56.3 159 66.8
1–3 positive 27.5 166 18.8 244 28.2 90 30.8 100 29.8 54 22.7
>3 positive 11.2 58 6.6 119 13.7 47 16.1 47 14.0 25 10.5
Unknown 13 24 7 12 5
ER status <0.001
Negative 18.8 121 17.3 219 31.9 116 48.9 75 28.3 28 15.1
Positive 81.2 578 82.7 468 68.1 121 51.1 190 71.7 157 84.9
Unknown 198 203 62 83 58
PR status <0.001
Negative 33.7 223 31.9 330 48.7 156 66.7 120 46.2 54 29.5
Positive 66.3 475 68.1 347 51.3 78 33.3 140 53.8 129 70.5
Unknown 199 213 65 88 60
Her2-Neu status 0.347
Negative 85.2 346 88.7 278 82.7 92 81.4 113 80.7 73 88.0
Positive 14.8 44 11.3 58 17.3 21 18.6 27 19.3 10 12.0
Unknown 507 554 186 208 160
Abbreviations: LRR = locoregional recurrence, SP = second primary, DFI = disease-free interval, ER = oestrogen receptor, PR = progesterone receptor,
Her2-Neu = human epidermal growth factor receptor 2
doi:10.1371/journal.pone.0120832.t001
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Table 2. Primary treatment and recurrence characteristics, for LRRs stratified by length of the DFI and tested for differences between the DFI
groups.
Without LRR/SP SP LRR Length of DFI P
Short Medium Long
% N % N % N % N % N %
Number of surgeries 0.684
1 88.9 766 85.4 780 87.6 259 86.6 303 87.1 218 89.7
2 10.5 124 13.8 100 11.2 36 12.0 40 11.5 24 9.9
3 0.6 7 0.8 10 1.1 4 1.3 5 1.4 1 0.4
Type of surgery <0.001
Breast conserving 56.3 517 57.6 395 44.4 95 31.8 156 44.8 144 59.3
Non-breast conserving 43.5 380 42.4 495 55.6 204 68.2 192 55.2 99 40.7
Time from incidence to last surgery 0.145
<30 days 74.0 619 69.0 637 71.6 207 69.2 250 71.8 180 74.1
30–60 days 22.0 223 24.9 207 23.3 69 23.1 82 23.6 56 23.0
>60 days 4.0 55 6.1 46 5.2 23 7.7 16 4.6 7 2.9
Axillary lymph node dissection 0.004
No 49.4 545 60.8 425 47.8 126 42.1 162 46.6 137 56.4
Yes 50.7 352 39.2 465 52.2 173 57.9 186 53.4 106 43.6
Chemotherapy 0.003
No 64.1 692 77.1 579 65.1 177 59.2 224 64.4 178 73.3
Yes 35.9 205 22.9 311 34.9 122 40.8 124 35.6 65 26.7
Radiotherapy <0.001
No 34.3 313 34.9 447 50.2 184 61.5 174 50.0 89 36.6
Yes 65.7 584 65.1 443 49.8 115 38.5 174 50.0 154 63.4
Hormone therapy 0.054
No 58.2 682 76.0 643 72.2 231 77.3 245 70.4 167 68.7
Yes 41.8 215 24.0 247 27.8 68 22.7 103 29.6 76 31.3
Length of DFI
Short na 248 27.6 na na na na
Medium 334 37.2
Long 315 35.1
Type of recurrence 0.378
LR na na 584 65.6 184 61.5 233 67.0 167 68.7
RR 240 27.0 88 29.4 93 26.7 59 24.3
Synchronous LRRs 66 7.4 27 9.0 22 6.3 17 7.0
Surgery of LRR/SP 0.001
No na 38 4.2 368 41.3 147 49.2 138 39.7 83 34.2
Yes 859 95.8 522 58.7 152 50.8 210 60.3 160 65.8
Chemotherapy of LRR/SP 0.172
No na 705 78.6 625 70.2 198 66.2 250 71.8 177 72.8
Yes 192 21.4 265 29.8 101 33.8 98 28.2 66 27.2
Radiotherapy of LRR/SP <0.001
No na 467 52.1 432 48.5 118 39.5 172 49.4 142 58.4
Yes 430 47.9 458 51.5 181 60.5 176 50.6 101 41.6
Hormone therapy of LRR/SP 0.001
No na 597 66.6 562 63.1 213 71.2 211 60.6 138 56.8
Yes 300 33.4 328 36.9 86 28.8 137 39.4 105 43.2
Abbreviations: LRR = locoregional recurrence, SP = second primary, LR = local recurrence, RR = regional recurrence, na = not applicable.
doi:10.1371/journal.pone.0120832.t002
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Table 3. Treatment of the primary tumour against the treatment of LRRs.
Primary tumour
Breast-conserving surgery Chemotherapy Radiotherapy Hormone therapy
LRR No Yes No Yes No Yes No Yes
(n = 506) (n = 395) (n = 589) (n = 312) (n = 447) (n = 454) (n = 649) (n = 252)
Surgery No 29%* 13%* 24%* 18%* 24%* 18%* 28%* 13%*
(n = 385)
Yes 27%* 32%* 41%* 17%* 26%* 32%* 44%* 15%*
(n = 516)
Chemotherapy No 40% 30% 51%* 19%* 38%* 32%* 49%* 21%*
(n = 682)
Yes 16% 14% 14%* 16%* 12%* 17%* 23%* 7%*
(n = 219)
Radiotherapy No 19%* 30%* 33%* 15%* 17%* 32%* 37% 12%
(n = 457)
Yes 37%* 15%* 32%* 20%* 33%* 18%* 36% 16%
(n = 444)
Hormone therapy No 34% 29% 36%* 27%* 29%* 34%* 49%* 14%*
(n = 589)
Yes 22% 15% 29%* 8%* 21%* 16%* 23%* 14%*
(n = 312)
* indicates a significant difference Abbreviations: LRR = locoregional recurrence.
doi:10.1371/journal.pone.0120832.t003
Table 4. Treatment of the primary tumour against the treatment of SP tumours.
Primary tumour
Breast-conserving surgery Chemotherapy Radiotherapy Hormone therapy
SP No Yes No Yes No Yes No Yes
(n = 299) (n = 446) (n = 585) (n = 160) (n = 248) (n = 497) (n = 585) (n = 160)
Surgery No 3%* 1%* 4% 1% 3%* 2%* 3% 1%
(n = 34)
Yes 39%* 56%* 73% 22% 32%* 63%* 73% 23%
(n = 711)
Chemotherapy No 34% 44% 64%* 14%* 29% 50% 60%* 19%*
(n = 551)
Yes 8% 13% 13%* 9%* 6% 15% 16%* 5%*
(n = 194)
Radiotherapy No 33%* 19%* 39% 13% 28%* 25%* 37%* 15%*
(n = 373)
Yes 9%* 38%* 38% 10% 7%* 41%* 39%* 9%*
(n = 372)
Hormone therapy No 27% 39% 51% 15% 22% 45% 53%* 14%*
(n = 477)
Yes 15% 18% 26% 7% 13% 20% 24%* 10%*
(n = 268)
* indicates a significant difference. Abbreviations: SP = second primary.
doi:10.1371/journal.pone.0120832.t004
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radiotherapy and less hormone therapy compared to women with a medium or long DFI
(Table 2).
Survival
Ten year overall survival was 84% for women without recurrence, 49% for women with a LRR
and 72% for women with a SP tumour. Ten year overall survival for patients with a LRR and a
short DFI was 31%, 50% for medium and 70% for women with long DFIs (Fig 1A). Patients
with a SP tumour demonstrated higher ten year overall survival rates with 69% for short DFIs,
72% for medium and 76% for long DFIs (Fig 1B). Table 5 shows the multivariable Cox regres-
sion analyses. Compared to short DFIs, women with a medium DFI and a LRR showed better
survival after recurrence (Fig 1C) (Hazard Ratio (HR) 0.81, 95% CI 0.65–1.01) as well as
women with a long DFI (HR 0.65, 95% CI 0.48–0.88). No significant association was found for
the DFI and survival after SP tumours after adding covariates (Fig 1D).
Convergence of the imputed dataset was adequate and the results of the Cox proportional
hazards model on the multiple imputed data were comparable to those of the complete case
analysis. Continuous DFI (expressed in days) also displayed significant influence in the multi-
variable analysis for LRR (HR 0.9997 per day), but did not result in a better model fit. There
was no interaction identified for the complete model. The Cox proportional hazards assump-
tion was not violated when tested both numerically and graphically. The variables that influ-
enced survival after recurrence the most were age category and whether or not the LRR or SP
tumour had been surgically removed.
Fig 1. Kaplan-Meier curves divided in short, medium and long DFIs for (A) overall survival in patients with a LRR, (B) overall survival in patients
with a SP, (C) survival after recurrence in patients with a LRR, and (D) survival after recurrence for patients with a SP tumour. Abbreviations:
DFI = disease-free interval, LRR = locoregional recurrence, SP = second primary.
doi:10.1371/journal.pone.0120832.g001
Survival after LRR or SP Breast Cancer: Impact of the DFI
PLOS ONE | DOI:10.1371/journal.pone.0120832 April 10, 2015 7 / 12
Discussion
To the best of our knowledge, this is the first time the relation between the DFI and survival
after a LRR or SP tumour has been explored on a large scale in a nationwide population-based
registry. The DFI before a LRR is a prognostic factor for overall survival and survival after a
LRR, with longer DFIs showing longer survival. Besides the DFI, age and surgical removal of
the recurrence were significantly associated with survival after recurrence. After adding covari-
ables in the multivariable analysis, length of the DFI before a LRR remained of significant influ-
ence on survival after the LRR, which suggests that it is an independent prognostic factor. No
significant independent association was found for the DFI and survival after SP tumours. Pa-
tients with a short DFI and a LRR show on average less differentiated cells (grade III) and a
larger primary tumour compared to the patients with medium and long DFIs, which suggests a
more biological aggressive form of breast cancer. Moreover, short DFIs are significantly associ-
ated with subsequent DM [16, 25]. Another possible explanation is that patients with a short
DFI still had to recover fully from the treatment given for the primary tumour. In the multivar-
iable analysis, the effect of the DFI on survival after a SP tumour was not significant. SP tu-
mours are new breast cancers independent of the primary tumour and the prognosis is
therefore also independent of the DFI after the primary tumour.
Consistent with previous studies, age<70, good differentiation of the tumour cells (grade I,
II), smaller tumour size, negative lymph nodes, positive hormone status, no axillary lymph
node dissection, radiotherapy and surgical removal of the recurrence have been identified to be
associated with better survival [16–18, 26]. Both chemotherapy and hormone therapy are
known to have a positive influence on survival after primary breast cancer [19, 27]. Yet after
adding covariates in the proportional hazards models chemotherapy and hormone therapy
were not of significant influence on survival after a LRR or a SP tumour. In the univariable
analysis women who received chemotherapy or hormone therapy showed worse survival com-
pared to those without (HR 1.61, 95% CI 1.37–1.90 for chemotherapy; HR 1.45, 95% CI 1.23–
1.73 for hormone therapy). Recurrence of the breast cancer, possibly even during the adjuvant
treatment period, might suggest resistance to the treatment [28, 29]. The SP tumours were in
95% of the cases contralateral. Most of the patients with a SP tumour (96%) had undergone
surgery, which is associated with higher survival after the SP tumour. However, this positive ef-
fect cannot solely be contributed to the influence of the surgery, but also the selection of pa-
tients that are eligible for surgery. Of the patients with a LRR, 41% did not receive surgery for
their recurrence. In case of a short DFI this proportion was 49%. However, this could be ex-
plained by the higher amount of non-breast conserving surgeries for the primary tumour in
this group (68% received mastectomy). Typical reasons for withholding from surgical treat-
ment include diffuse infiltration, inflammatory changes, subsequent DM, high age or patient
preference [30, 31]. Besides less surgery, women with a short DFI also received less hormone
therapy for their LRR (Table 2). Consistent with previous studies we found that women with
hormone negative primary tumours have on average a shorter DFI, which resulted in less hor-
mone therapy in this group [32]. The cohort represented patients who were diagnosed in the
period 2003–2006 and treated at that time, which could explain the lower percentage of hor-
mone and chemotherapy compared to current treatment (data not shown). Another reason is
the exclusion of patients who received neo-adjuvant systemic therapy (4% of the patients),
while it is uncertain with which stage the patients should be included in the model. LRRs and
SP tumours show differences in characteristics and prognosis and therefore need a different ap-
proach. In some studies the distinction between SP tumours and LRR is not made [14, 16, 33],
which might overestimate the prognosis after a LRR.
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The advantage of using the large cohort from the population-based NCR—including almost
all breast cancer patients diagnosed between 2003 and 2006—is the reflection of daily practice.
However, only limited information was available regarding the characteristics of the recur-
rences. The median overall survival in this study is 8.1 years, which could be considered short
in a tumour with such a high ten year survival rate. Still, the balance between sufficiently long
follow-up and relevance of the results for the present clinical situation needs to be considered.
Table 5. Multivariable Cox regression analysis after multiple imputation.
LRR (n = 890) SP (n = 745)
Univariable Mutivariable Univariable Multivariable
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
DFI
Short Ref. Ref. Ref. Ref.
Medium 0.63 0.51–0.78 <0.001 0.81 0.65–1.01 0.066 1.26 0.90–1.78 0.184 1.14 0.80–1.61 0.475
Long 0.39 0.29–0.52 <0.001 0.65 0.48–0.88 0.005 1.37 0.93–2.01 0.113 1.42 0.96–2.09 0.079
Type of recurrence
LR Ref. Ref. na na
RR 1.44 1.17–1.78 <0.001 0.83 0.64–1.07 0.144
Synchronous LRRs 2.03 1.47–2.83 <0.001 1.99 1.41–2.79 <0.001
Age
<70 years Ref. Ref. Ref. Ref.
70 years 2.28 1.86–2.79 <0.001 2.29* 1.85–2.84 <0.001 2.59* 1.93–3.48 <0.001 2.28* 1.67–3.12 0.002
Grade
I, II Ref. Ref. Ref. Ref.
III 2.61* 2.12–3.21 <0.001 1.42 1.10–1.82 0.006 1.45 1.05–2.00 0.023 1.12 0.75–1.67 0.570
Tumour size
2 cm Ref. Ref. Ref. Ref.
>2 cm 2.60 2.13–3.18 <0.001 1.47 1.19–1.83 <0.001 1.76 1.32–2.36 <0.001 1.42 1.03–1.96 0.033
Lymph node status
Negative Ref. Ref. Ref. Ref.
1–3 positive 1.71 1.37–2.14 <0.001 1.15 0.86–1.54 0.355 1.66 1.19–2.32 0.003 1.36 0.92–2.02 0.123
>3 positive 4.06 3.17–5.20 <0.001 2.06 1.48–2.88 <0.001 1.89 1.17–3.06 0.010 1.05 0.61–1.82 0.864
Hormone receptor status
Other Ref. Ref. Ref. Ref.
ER/PR negative 2.49 2.02–3.06 <0.001 1.64 1.29–2.08 <0.001 1.45 0.99–2.13 0.055 1.30 0.82–2.05 0.268
Lymph node dissection
No Ref. Ref. Ref. Ref.
Yes 2.09 2.02–3.06 <0.001 1.40 1.05–1.86 0.023 1.80* 1.36–2.39 <0.001 1.28 0.90–1.83 0.170
Radiotherapy of LRR/SP
No Ref. Ref. Ref. Ref.
Yes 1.09 0.90–1.32 0.381 0.94 0.76–1.16 0.575 0.73 0.55–0.97 0.032 1.04 0.76–1.41 0.812
Surgery of LRR/SP
No Ref. Ref. Ref. Ref.
Yes 0.42* 0.35–0.51 <0.001 0.49* 0.39–0.61 <0.001 0.13* 0.09–0.19 <0.001 0.17* 0.11–0.27 <0.001
Abbreviations: HR = hazard rate, CI = Confidence Interval, DFI = disease-free interval, LR = local recurrence, RR = regional recurrence,
LRR = locoregional recurrence, SP = second primary, ER = oestrogen receptor, PR = progesterone receptor, na = not applicable.
* indicates most influencing factors.
doi:10.1371/journal.pone.0120832.t005
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The changes and improvements in the treatment of breast cancer in more recent years can, by
definition, not be reflected in a study with a long follow-up. Since only first or synchronous re-
currences are registered by the NCR, no correction is possible for subsequent recurrences. DM
after breast cancer is considered responsible for most of the morbidity and virtually all mortali-
ty associated with breast cancer. If a LRR was followed by a DM, this would drastically influ-
ence prognosis [34, 35]. Therefore, an improvement of the registry would be to register not
only first but also possible subsequent recurrences. Furthermore, knowledge about cause-spe-
cific death can help improve future research. Because of the observational design and a lack of
detailed information on breast cancer-specific survival and comorbidity, results should be in-
terpreted with caution. However, Doyle et al. [36] found no difference in cause-specific and
overall survival after a recurrence in the first five years and only a 3% difference after ten years.
Conclusion
This is the first study to explore the association between the DFI and survival after recurrence
in a nationwide population-based registry and it contributes to insight into prognosis after
LRR or SP breast cancer. The results of this study confirm that the DFI before a LRR is an inde-
pendent prognostic factor for survival after a LRR, with longer DFIs showing longer survival.
Furthermore, age and surgical removal of the recurrence greatly impact survival after recur-
rence. However, no significant independent association was found for the DFI and survival
after SP tumours.
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